POLYSACCHARIDE PEPTIDE: A NOVEL ANTI-INFLAMMATION IN REDUCING INTIMA MEDIA PROLIFERATION IN DIABETIC RATS

Diabetes Mellitus (DM) is a risk factor equivalent to Coronary Artery Disease (CAD). DM and CAD involves a chronic inflammatory process. Inflammatory cytokines are involved in both diseases, either DM or CAD. This study was aimed to evaluate polysaccharide peptide (PsP) of the extract of Ganoderma lucidum as an anti-inflammatory that inhibits the process atherogenesis in diabetic rats model. The study was experimental post-test with control group design. Thirty Wistar rats were divided into 5 groups: 1 group of normal rats as control group and 4 groups with High Fat Diet (HFD) and low dose streptozotocin (30 mg/kgBW) injection sc, treated with placebo and PsP dose 50,150,300 mg/KgBW respectively. Parameters measured are level of interleukin-6 (IL - 6), high sensitive C-reactive protein (hsCRP), and intima media thickness (IMT). After 5 weeks of treatment there were significant lower levels of IL?6 (p=0.000), atherosclerosis plaque area (p=0.000), IMT (p=0.000) and lower of hsCRP level (p=0.079) descriptively in the treatment group of PSP 150 and 300 mg/kgBW. Based on this study, PsP is a novel promising anti-inflammation to inhibit the process of atherogenesis in diabetes mellitus rats model.